RGC
Regencell Bioscience Holdings Limited
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · HK
$6.89
+6.33%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 40.8K | 392.7K | 745.6K | 769.7K | 604.4K |
| Gross Profit | (40.8K) | (392.7K) | (745.6K) | (769.7K) | (604.4K) |
| Operating Expenses | |||||
| R&D Expense | 1.4M | 948.3K | 1.1M | 1.6M | 2.5M |
| SG&A Expense | 7.7M | 2.4M | 2.9M | 4.7M | 5.1M |
| General & Admin Expense | 2.8M | 2.4M | 2.8M | 4.4M | 5.1M |
| Selling & Marketing Expense | 4.4K | 8.0K | 125.4K | 262.7K | 25.3K |
| Other Expenses | (55.87) | — | — | — | — |
| Total Operating Expenses | 9.1M | 3.4M | 4.0M | 6.3M | 7.6M |
| Cost and Expenses | 9.1M | 3.8M | 4.7M | 6.3M | 7.6M |
| Operating Income (EBIT) | (9.1M) | (3.8M) | (4.7M) | (6.3M) | (7.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 208.4K | 185.8K | 373.5K | 211.3K | 23.2K |
| Non-Operating Income (excl Interest) | (185.8K) | (185.8K) | (373.5K) | (211.3K) | — |
| EBT (Pre-Tax Income) | (8.9M) | (3.6M) | (4.4M) | (6.1M) | (7.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (8.9M) | (3.6M) | (4.3M) | (5.9M) | (7.4M) |
| Earnings from Cont. Ops | (8.9M) | (3.6M) | (4.4M) | (6.1M) | (7.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.9M) | (3.6M) | (4.3M) | (5.9M) | (7.4M) |
| Per Share | |||||
| Basic EPS | ($0.02) | ($0.01) | ($0.01) | ($0.01) | ($0.02) |
| Diluted EPS | ($0.02) | ($0.01) | ($0.01) | ($0.01) | ($0.02) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 494.5M | 494.5M | 494.5M | 494.5M | 494.5M |
| Diluted Shares Outstanding | 494.5M | 494.5M | 494.5M | 494.5M | 494.5M |
| Profitability Metrics | |||||
| EBITDA | (8.8M) | (3.2M) | (3.6M) | (5.3M) | (7.0M) |
| D&A | 117.4K | 392.7K | 745.6K | 769.7K | 604.4K |
| EBIT | (8.9M) | (3.6M) | (4.4M) | (6.1M) | (7.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025